Pro zobrazení tohoto obsahu je třeba být přihlášen.
Author Archives for m.popovic@wemakemedia.cz
A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (mBC) (TREnd trial).
29 septembra, 2020 8:30 pm Leave your thoughtsMeeting: 2017 ASCO Annual Meeting Track: Title:Breast Cancer-Metastatic Abstract number: 1002 Citation: J Clin Oncol 35, 2017...
APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC)
29 septembra, 2020 8:30 pm Leave your thoughtsMeeting: 2017 ASCO Annual Meeting Track: Breast Cancer – Local/Regional/Adjuvant Abstract number: LBA500 Citation: J Clin Oncol...
Pertuzumab Reduced Risk of Invasive Disease–Free Survival Compared With Placebo in APHINITY
29 septembra, 2020 8:30 pm Leave your thoughtsJune 5, 2017 Pertuzumab improved invasive disease–free survival (IDFS) in patients with HER2-positive, early-stage breast cancer when added to...
Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)
29 septembra, 2020 8:30 pm Leave your thoughtsMeeting: 2017 ASCO Annual Meeting Track: Oral Abstract Session Breast Cancer – Metastatic Abstract number: LBA4 Citation:...
OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
29 septembra, 2020 8:30 pm Leave your thoughtsMeeting: 2017 ASCO Annual Meeting Track: Oral Abstract Session Breast Cancer – Metastatic Abstract number: LBA4 Citation:...
Olaparib Improves Outcomes in BRCA-Mutated Metastatic Breast Cancer
29 septembra, 2020 8:30 pm Leave your thoughtsOlaparib tablet monotherapy yielded improved progression-free survival compared with standard-of-care chemotherapy among women with HER2-negative metastatic breast cancer and a...
Aktuální výsledky klinických studií
29 septembra, 2020 8:30 pm Leave your thoughtsLetošní konference ASCO 2017 přinesla řadu zajímavých výsledků a naději na opětovné zlepšení přežití pacientů so solidními nádory, včetně karcinomu prsu. ...
Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study
29 septembra, 2020 8:29 pm Leave your thoughtsMeeting: 2017 ASCO Annual Meeting Track: Gastrointestinal (Noncolorectal) Cancer Abstract number: 4014 Citation: J Clin Oncol 35,...
KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer
29 septembra, 2020 8:29 pm Leave your thoughtsMeeting: 2017 ASCO Annual Meeting Track: Gastrointestinal (Noncolorectal) Cancer Abstract number: 4003 Citation: J Clin Oncol 35,...
Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)
29 septembra, 2020 8:29 pm Leave your thoughtsMeeting: 2017 ASCO Annual Meeting Track: Gastrointestinal (Noncolorectal) Cancer Abstract number: 4001 Citation: J Clin Oncol 35,...